CAG
PRME icon

Crestwood Advisors Group’s Prime Medicine PRME Stock Holding History

Crestwood Advisors Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Sell
32,041
-333
-1% -$1.11K ﹤0.01% 853
2026
Q1 		$113K Buy
32,374
+401
+1% +$1.53K ﹤0.01% 756
2025
Q4 		$111K Buy
31,973
+286
+0.9% +$1.27K ﹤0.01% 686
2025
Q3 		$176K Hold
31,687
– – ﹤0.01% 559
2025
Q2 		$78.3K Hold
31,687
– – ﹤0.01% 526
2025
Q1 		$63.1K Hold
31,687
– – ﹤0.01% 494
2024
Q4 		$92.5K Buy
+31,687
New +$111K ﹤0.01% 454

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Crestwood Advisors Group's PRME Position: Q2 2026 in Review

Crestwood Advisors Group reduced its Prime Medicine (PRME) stake by 1% in Q2 2026, selling an estimated $1.11K and leaving 32,041 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Crestwood Advisors Group first reported a position in PRME in Q4 2024 and has held it in 7 quarters since. The position peaked at $176K in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Crestwood Advisors Group held 32,041 shares of Prime Medicine worth $118K as of Q2 2026.
  • Crestwood Advisors Group sold 333 Prime Medicine shares in Q2 2026, an estimated $1.11K.
  • Prime Medicine made up ﹤0.01% of Crestwood Advisors Group's portfolio in Q2 2026, its #853 holding.
  • Crestwood Advisors Group first reported a position in Prime Medicine in Q4 2024 and has held it in 7 quarters since.
  • Crestwood Advisors Group's Prime Medicine position peaked at $176K in Q3 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.